Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance

Wang,Weiwei; Zhang,Lijun; Liu,Liang; Zheng,Yongfa; Zhang,Yong; Yang,Siyuan; Shi,Rongliang; Wang,Shaojia

doi:10.3892/or.2017.5443

Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance

Authors:
- Weiwei Wang
- Lijun Zhang
- Liang Liu
- Yongfa Zheng
- Yong Zhang
- Siyuan Yang
- Rongliang Shi
- Shaojia Wang
View Affiliations

Affiliations: Department of Chest Surgery, The Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan 650031, P.R. China, Department of General Surgery, Ganmei Affiliated Hospital of Kunming Medical University (The First People's Hospital of Kunming), Kunming, Yunnan 650032, P.R. China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China, Department of Oncology, Renming Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Oncology, Kunming Medical University, Kunming, Yunnan 650031, P.R. China, Department of General Surgery, Minhang Hospital, Fudan University, Shanghai 201199, P.R. China
Published online on: February 14, 2017 https://doi.org/10.3892/or.2017.5443
Pages: 1989-1997
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is a common fatal malignancy in both men and women. Xuanwei, Yunnan has the highest incidence of lung cancer in China. The area has a specific risk factor in the domestic combustion of bituminous coal, and lung cancer patients from this area tend to be resistant to platinum-based treatments. However, little is known about the mechanism of platinum resistance in patients from Xuanwei. Herein, we used lentiviral infection with shRNA to silence expression of the DNA repair enzyme ERCC1 in XWLC05 both in its RNA and protein expression level, a lung adenoma cell line derived from a patient from Xuanwei. ERCC1 expression in this cell line is high and contributes to its resistance to cisplatin. Suppression of ERCC1 decreased XWLC05 proliferation in vitro (IC50 of cisplatin 1.34 µM for shRNA-infected cells vs. 4.54 µM for control cells) and increased the apoptotic rate after treatment with cisplatin (81.2% shRNA cells vs. 58% control cells, P<0.05). Progression-free survival was longer in ERCC1-negative lung adenoma patients than those with high ERCC1 levels (30 vs. 11 months, P<0.0001). ERCC1 expression was identified as a prognostic marker for overall survival in the patient cohort with operable lesions. Taken together, our data identify ERCC1 as a disease marker in lung adenoma patients from Xuanwei and confirm the significance of resection for the subsequent effect of platinum treatment in these patients. Additional studies are needed to determine the mechanism of ERCC1-induced platinum resistance in lung adenoma patients from Xuanwei.

View Figures

View References

1	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
2	Downward GS, Hu W, Large D, Veld H, Xu J, Reiss B, Wu G, Wei F, Chapman RS, Rothman N, et al: Heterogeneity in coal composition and implications for lung cancer risk in Xuanwei and Fuyuan counties, China. Environ Int. 68:94–104. 2014. View Article : Google Scholar : PubMed/NCBI
3	Liu ZY, He XZ and Chapman RS: Smoking and other risk factors for lung cancer in Xuanwei, China. Int J Epidemiol. 20:26–31. 1991. View Article : Google Scholar : PubMed/NCBI
4	Shen M, Chapman RS, He X, Liu LZ, Lai H, Chen W and Lan Q: Dietary factors, food contamination and lung cancer risk in Xuanwei, China. Lung Cancer. 61:275–282. 2008. View Article : Google Scholar : PubMed/NCBI
5	Lan Q, Chapman RS, Schreinemachers DM, Tian L and He X: Household stove improvement and risk of lung cancer in Xuanwei, China. J Natl Cancer Inst. 94:826–835. 2002. View Article : Google Scholar : PubMed/NCBI
6	Kim C, Chapman RS, Hu W, He X, Hosgood HD, Liu LZ, Lai H, Chen W, Silverman DT, Vermeulen R, et al: Smoky coal, tobacco smoking, and lung cancer risk in Xuanwei, China. Lung Cancer. 84:31–35. 2014. View Article : Google Scholar : PubMed/NCBI
7	Reed E: ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res. 11:6100–6102. 2005. View Article : Google Scholar : PubMed/NCBI
8	Sodja E, Knez L, Kern I, Ovčariček T, Sadikov A and Cufer T: Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Eur J Cancer. 48:3378–3385. 2012. View Article : Google Scholar : PubMed/NCBI
9	Siddik ZH: Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
10	Martin LP, Hamilton TC and Schilder RJ: Platinum resistance: The role of DNA repair pathways. Clin Cancer Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zamble DB, Mu D, Reardon JT, Sancar A and Lippard SJ: Repair of cisplatin - DNA adducts by the mammalian excision nuclease. Biochemistry. 35:10004–10013. 1996. View Article : Google Scholar : PubMed/NCBI
12	Selby CP and Sancar A: Mechanisms of transcription-repair coupling and mutation frequency decline. Microbiol Rev. 58:317–329. 1994.PubMed/NCBI
13	Mu D, Hsu DS and Sancar A: Reaction mechanism of human DNA repair excision nuclease. J Biol Chem. 271:8285–8294. 1996. View Article : Google Scholar : PubMed/NCBI
14	Smith S, Su D, de la Rigault Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H and Katsaros D: ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J Clin Oncol. 25:5172–5179. 2007. View Article : Google Scholar : PubMed/NCBI
15	Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB and DeLoia JA: Gynecologic Oncology Group Phase III Trial: Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol. 26:3598–3606. 2008. View Article : Google Scholar : PubMed/NCBI
16	Yamada Y, Boku N, Nishina T, Yamaguchi K, Denda T, Tsuji A, Hamamoto Y, Konishi K, Tsuji Y, Amagai K, et al: Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: Correlative study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol. 24:2560–2565. 2013. View Article : Google Scholar : PubMed/NCBI
17	Squires MH III, Fisher SB, Fisher KE, Patel SH, Kooby DA, El-Rayes BF, Staley CA III, Farris AB III and Maithel SK: Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. Cancer. 119:3242–3250. 2013. View Article : Google Scholar : PubMed/NCBI
18	Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, Kimmig R, et al: ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance. Clin Chem. 60:1282–1289. 2014. View Article : Google Scholar : PubMed/NCBI
19	Hatch SB, Swift LP, Caporali S, Carter R, Hill EJ, MacGregor TP, D'Atri S, Middleton MR, McHugh PJ and Sharma RA: XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection. Int J Cancer. 134:1495–1503. 2014. View Article : Google Scholar : PubMed/NCBI
20	Bauman JE, Austin MC, Schmidt R, Kurland BF, Vaezi A, Hayes DN, Mendez E, Parvathaneni U, Chai X, Sampath S, et al: ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: Results from a randomised, phase II trial. Br J Cancer. 109:2096–2105. 2013. View Article : Google Scholar : PubMed/NCBI
21	Cecere F, Bria E and Rosell R: DNA repair by ERCC1 in non-small-cell lung cancer. N Engl J Med. 355:2590–2591; author reply 2591. 2006. View Article : Google Scholar : PubMed/NCBI
22	Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Gadgeel S, Zhao X, Schreiber F, Brahmer J, et al: Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 31:2404–2412. 2013. View Article : Google Scholar : PubMed/NCBI
23	Soria JC: ERCC1-tailored chemotherapy in lung cancer: The first prospective randomized trial. J Clin Oncol. 25:2648–2649. 2007. View Article : Google Scholar : PubMed/NCBI
24	Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, Yamamoto S, Tsuta K, Nokihara H, Yamamoto N, Sekine I, et al: Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 28:4945–4952. 2010. View Article : Google Scholar : PubMed/NCBI
25	Weiwei W, Zaoxiu H, Deguang W and Yong Z: Comparison of ERCC1 expression in lung adenoma tissue from Xuanwei of Yunnan province and other areas. Shangdong Med. 22:67–68. 2016.
26	Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, et al: Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: A Gynecologic Oncology Group study. Gynecol Oncol. 125:421–426. 2012. View Article : Google Scholar : PubMed/NCBI
27	Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al: IALT Bio Investigators: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Zhao J, Yang L, Mao L, An T, Bai H, Wang S, Liu X, Feng G and Wang J: Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer. Med Oncol. 27:484–490. 2010. View Article : Google Scholar : PubMed/NCBI
29	Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, et al: Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 64:98–104. 2009. View Article : Google Scholar : PubMed/NCBI
30	Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, et al: Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 65:377–382. 2009. View Article : Google Scholar : PubMed/NCBI
31	Holm B, Mellemgaard A, Skov T and Skov BG: Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine. J Clin Oncol. 27:4254–4259. 2009. View Article : Google Scholar : PubMed/NCBI
32	Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A and Aizawa H: Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci. 98:1336–1343. 2007. View Article : Google Scholar : PubMed/NCBI
33	Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, et al: Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res. 14:2878–2886. 2008. View Article : Google Scholar : PubMed/NCBI
34	Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, et al: Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 371:2189–2199. 2014. View Article : Google Scholar : PubMed/NCBI
35	Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 348:124–128. 2015. View Article : Google Scholar : PubMed/NCBI
36	Simon GR, Sharma S, Cantor A, Smith P and Bepler G: ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest. 127:978–983. 2005. View Article : Google Scholar : PubMed/NCBI
37	Schneider JG, Farhadfar N, Sivapiragasam A, Geller M, Islam S and Selbs E: Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer. Oncologist. 19:459–465. 2014. View Article : Google Scholar : PubMed/NCBI
38	Cheng H, Zhang Z, Rodriguez-Barrueco R, Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R and Halmos B: Functional genomics screen identifies YAP1 as a key determinant to enhance treatment sensitivity in lung cancer cells. Oncotarget. 7:28976–28988. 2016.PubMed/NCBI
39	Jiang P, Wu X, Wang X, Huang W and Feng Q: NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells. Oncotarget. 7:43337–43351. 2016.PubMed/NCBI
40	Reed E: Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology. 27:187–201. 1998. View Article : Google Scholar : PubMed/NCBI
41	Olaussen KA and Postel-Vinay S: Predictors of chemotherapy efficacy in non-small-cell lung cancer: A challenging landscape. Ann Oncol. 27:2004–2016. 2016. View Article : Google Scholar : PubMed/NCBI
42	Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: A phase III trial in non-small-cell lung cancer. J Clin Oncol. 25:2747–2754. 2007. View Article : Google Scholar : PubMed/NCBI